Renaissance Group LLC Has $36.57 Million Position in AbbVie Inc. $ABBV

Renaissance Group LLC boosted its stake in AbbVie Inc. (NYSE:ABBV) by 6.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 157,948 shares of the company’s stock after acquiring an additional 9,453 shares during the period. AbbVie accounts for 1.4% of Renaissance Group LLC’s investment portfolio, making the stock its 23rd largest holding. Renaissance Group LLC’s holdings in AbbVie were worth $36,571,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently modified their holdings of the company. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie during the 2nd quarter valued at $26,000. Spurstone Advisory Services LLC bought a new stake in AbbVie in the second quarter valued at $28,000. Financial Gravity Companies Inc. acquired a new position in shares of AbbVie during the second quarter valued at about $36,000. Delos Wealth Advisors LLC bought a new position in shares of AbbVie during the 2nd quarter worth about $39,000. Finally, Cloud Capital Management LLC acquired a new stake in shares of AbbVie in the 3rd quarter valued at about $53,000. 70.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. HSBC raised AbbVie from a “hold” rating to a “buy” rating and upped their price target for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. JPMorgan Chase & Co. increased their target price on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. UBS Group lowered their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday. Finally, Berenberg Bank set a $275.00 price objective on shares of AbbVie in a report on Tuesday, January 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $251.00.

AbbVie Price Performance

NYSE ABBV opened at $223.50 on Friday. The company has a fifty day moving average price of $223.74 and a 200-day moving average price of $219.41. The firm has a market cap of $395.01 billion, a price-to-earnings ratio of 94.70, a PEG ratio of 0.89 and a beta of 0.35. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Morgan Stanley raised its price target to $270 and kept an “overweight” call, signaling institutional analyst conviction that AbbVie has double‑digit upside from current levels. Read More.
• Positive Sentiment: Company forecasts for full‑year 2026 profit came in above estimates, driven by strong sales of newer immunology drugs (Skyrizi, Rinvoq), supporting the case for continued top‑line and earnings growth. Read More.
• Positive Sentiment: Market commentary and some analysts view the post‑earnings pullback as a buying opportunity, pointing to institutional accumulation, durable cash flow, and a strong dividend as anchors for medium‑term returns. Read More.
• Positive Sentiment: New real‑world Rinvoq data from Japan bolsters the drug’s addressable market for ankylosing spondylitis and reinforces growth prospects for AbbVie’s immunology franchise. Read More.
• Neutral Sentiment: Management framed the earnings call around “new growth engines” — Skyrizi/Rinvoq and other launches taking the lead in driving growth, which supports the long‑term story but doesn’t eliminate near‑term volatility. Read More.
• Neutral Sentiment: Q4 results beat on revenue and showed strong margin/earnings leverage, confirming product momentum even as some segments face headwinds. Read More.
• Negative Sentiment: Shares initially gapped down after the print as investors focused on a softer-than‑expected Q1 EPS and revenue outlook despite the quarter’s beats — a classic near‑term reaction to guidance misses. Read More.
• Negative Sentiment: AbbVie set Q1 2026 EPS guidance at $2.97–$3.01 (vs. ~3.11 consensus) and gave revenue guidance below the street, creating short‑term uncertainty about the cadence of 2026 growth. Read More.
• Negative Sentiment: Broader coverage highlighted investor “angst” and a bifurcated reaction — bullish on medium‑term fundamentals but worried about near‑term comps and valuation — keeping volatility elevated. Read More.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.